THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS. (12th June 2019)

• Record Type: Journal Article
• Authors: Advani, R.; Bartlett, N.L.; Smith, S.M.; Roschewski, M.; Popplewell, L.; Flinn, I.; Collins, G.; Ghosh, N.; LaCasce, A.; Asch, A.; Kline, J.; Kesevan, M.; Tran, T.; Lynn, J.; Huang, J.; Agoram, B.; Volkmer, J.; Takimoto, C.H.; Chao, M.P.; Mehta, A.
• Is Part Of: Hematological oncology. Volume 37(2019)Supplement 2
• Page Start: 89
• Page End: 90
• Publication Date: 2019-06-12
• Subjects: Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.57_2629
• Languages: English
• ISSNs: 0278-0232